# Hyperemic mYocardial Perfusion by adEnosine at diffeRent Doses

Study · id `cardio:ct-nct06578234` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06578234](<https://clinicaltrials.gov/study/NCT06578234>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06578234

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 180 participants.

## Technical summary

Registry record NCT06578234. Randomized; single masking; primary purpose diagnostic. Start 2024-10-23 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose diagnostic
- Phase: Phase 4
- Enrolled: 180 participants (planned count; ClinicalTrials.gov record NCT06578234, source copy `cardio:ctgov-nct06578234-2026-08-13`, retrieved 2026-10-26)
- Started: 2024-10-23 (actual) (ClinicalTrials.gov record NCT06578234, source copy `cardio:ctgov-nct06578234-2026-08-13`, retrieved 2026-10-26)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06578234, source copy `cardio:ctgov-nct06578234-2026-08-13`, retrieved 2026-10-26)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06578234, source copy `cardio:ctgov-nct06578234-2026-08-13`, retrieved 2026-10-26)
- Countries: Sweden (ClinicalTrials.gov record NCT06578234, source copy `cardio:ctgov-nct06578234-2026-08-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06578234-2026-08-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Hyperemic mYocardial Perfusion by adEnosine at diffeRent Doses
- Acronym: HYPER
- Condition: Chronic Coronary Syndrome
- Condition: Coronary Artery Disease
- Condition: Ischemic Heart Disease
- Intervention (Drug): Adenosine
- Lead sponsor: Region Skane
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Region Skane (`cardio:org-region-skane`)

## Provenance

Content hash: 80ecf9cac08543b24ade4cf000d80d1a854fc9b6bacd5022b9666c65e21a7593
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
